Deirdre Cohen named director of Mount Sinai’s Gastrointestinal Oncology Program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Deirdre J. Cohen, an expert in pancreatic and other gastrointestinal cancers, was named director of the Gastrointestinal Oncology Program and medical director of the Cancer Clinical Trials Office at The Tisch Cancer Institute at Mount Sinai Health System.

Cohen will also be an associate professor of medicine (hematology and medical oncology) at the Icahn School of Medicine at Mount Sinai. In these roles, she will conduct translational and clinical research, including studies that build upon scientific discoveries developed at Mount Sinai and collaborating institutions.

As director of the GI Oncology Program, Cohen will foster both clinical and research activities associated with GI cancers across the Mount Sinai cancer sites. She will also oversee the development of clinical trials in her role as medical director of the Cancer Clinical Trials Office.

Prior to joining Mount Sinai, Cohen was on the faculty in the Division of Medical Oncology at New York University for 13 years. Recently, she served as medical director for the Perlmutter Cancer Center Clinical Trials Office and acting director of NYU GI Medical Oncology.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login